Organogenesis Holdings Inc. (NASDAQ:ORGO) Sees Significant Drop in Short Interest

Organogenesis Holdings Inc. (NASDAQ:ORGO) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,520,000 shares, a decline of 18.2% from the November 15th total of 10,410,000 shares. Currently, 11.9% of the shares of the company are sold short. Based on an average trading volume of 655,500 shares, the short-interest ratio is presently 13.0 days.

Organogenesis Price Performance

Organogenesis stock traded down $0.13 during trading hours on Friday, hitting $3.40. 533,181 shares of the stock were exchanged, compared to its average volume of 843,073. The stock has a market capitalization of $450.77 million, a P/E ratio of -56.67 and a beta of 1.73. The business’s 50-day moving average is $3.43 and its two-hundred day moving average is $2.99. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis has a 12 month low of $2.16 and a 12 month high of $4.70.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The firm had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period last year, the firm posted $0.02 EPS. Equities research analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Activity at Organogenesis

In related news, CEO Gary S. Gillheeney sold 18,416 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $3.65, for a total value of $67,218.40. Following the sale, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. The trade was a 0.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 216,916 shares of company stock worth $784,832 over the last three months. Company insiders own 36.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors bought a new stake in shares of Organogenesis during the third quarter worth $36,000. Pallas Capital Advisors LLC acquired a new stake in Organogenesis in the second quarter worth about $38,000. Delap Wealth Advisory LLC bought a new stake in Organogenesis during the 2nd quarter worth about $40,000. Intech Investment Management LLC acquired a new position in Organogenesis during the 3rd quarter valued at about $43,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Organogenesis by 4,989.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after purchasing an additional 15,369 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.